Disclosed herein are FABP4 and FABP5 inhibitor compounds and their use in pharmaceutical compositions for treating diseases relating to fatty acid metabolism, including cancer. Also disclosed herein are methods for preparing the disclosed compounds.

Disclosed herein are FABP4 and FABP5 inhibitor compounds and their use in pharmaceutical compositions for treating diseases relating to fatty acid metabolism, including cancer. Also disclosed herein are methods for preparing the disclosed compounds.

Polymeric compositions are provided that include a furan 2,5-di-ester or tetrahydrofuran 2,5-di-ester plasticizer. The plasticizer has low odor, has good compatibility with a variety of polymers such as hydrophilic polymeric materials, and can be formed from renewable resources. Further, the plasticizer can be used at temperatures often encountered during hot melt processing of polymeric compositions.

Polymeric compositions are provided that include a furan 2,5-di-ester or tetrahydrofuran 2,5-di-ester plasticizer. The plasticizer has low odor, has good compatibility with a variety of polymers such as hydrophilic polymeric materials, and can be formed from renewable resources. Further, the plasticizer can be used at temperatures often encountered during hot melt processing of polymeric compositions.

The present disclosure provides treprostinil derivatives that can act as prodrugs of treprostinil. The treprostinil derivatives can be used to treat any conditions responsive to treatment with treprostinil, including pulmonary hypertension, such as pulmonary arterial hypertension.

The specification generally relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof, where A, U, V, W, X, Y, Z, R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 have the meanings defined herein. Such compounds are modulators of RXFP1 and may be useful as therapeutic agents. The specification also relates to the use of such compounds to treat or prevent diseases and conditions including heart failure, heart failure with preserved ejection fraction, heart failure with mid-range ejection fraction, heart failure with reduced ejection fraction, chronic kidney disease and acute kidney injury. The specification further relates to compositions comprising such compounds, intermediates useful in processes for preparing such compounds, and processes for preparing such compounds using such intermediates.

The present invention primarily relates to the use of a compound according to the general formula (I) wherein i) m is 1, n is 1, o is 0 or 1, Y is Hydrogen, or ii) m is 2, n is 0, o is 1, Y is methyl, and wherein X is O or methylene, R and R1 are each methyl or form together with the carbon atom attached to a carbonyl group, and R2 is methyl, ethyl, propyl, butyl, butan-2-one-4-yl, tetrahydrofuran-2-yl, or tetrahydrofuran-3-yl, as perfuming ingredients. Moreover, the present invention relates to perfume compositions and perfumed products comprising the before mentioned perfuming ingredients. Still more particularly, the invention relates to a method for producing said perfumed products and a method of imparting and/or increasing musk odor characteristics to perfumed products. This invention also relates to a process for the preparation of said compounds according to the general formula (I).

The present invention primarily relates to the use of a compound according to the general formula (I) wherein i) m is 1, n is 1, o is 0 or 1, Y is Hydrogen, or ii) m is 2, n is 0, o is 1, Y is methyl, and wherein X is O or methylene, R and R1 are each methyl or form together with the carbon atom attached to a carbonyl group, and R2 is methyl, ethyl, propyl, butyl, butan-2-one-4-yl, tetrahydrofuran-2-yl, or tetrahydrofuran-3-yl, as perfuming ingredients. Moreover, the present invention relates to perfume compositions and perfumed products comprising the before mentioned perfuming ingredients. Still more particularly, the invention relates to a method for producing said perfumed products and a method of imparting and/or increasing musk odor characteristics to perfumed products. This invention also relates to a process for the preparation of said compounds according to the general formula (I).

The invention relates to compounds useful in treating conditions associated with voltage-gated ion channel function, particularly conditions associated with sodium channel activity. More specifically, the invention concerns heterocyclic compounds (e.g., compounds according to any of Formulas (I)-(III) or Compounds (1)-(65) of Table 1) that are that are useful in treatment of conditions such as epilepsy, cancer, pain, migraine, Parkinson's Disease, mood disorders, schizophrenia, psychosis, tinnitus, amyotropic lateral sclerosis, glaucoma, ischaemia, spasticity disorders, obsessive compulsive disorder, restless leg syndrome and Tourette syndrome.

The invention relates to compounds useful in treating conditions associated with voltage-gated ion channel function, particularly conditions associated with sodium channel activity. More specifically, the invention concerns heterocyclic compounds (e.g., compounds according to any of Formulas (I)-(III) or Compounds (1)-(65) of Table 1) that are that are useful in treatment of conditions such as epilepsy, cancer, pain, migraine, Parkinson's Disease, mood disorders, schizophrenia, psychosis, tinnitus, amyotropic lateral sclerosis, glaucoma, ischaemia, spasticity disorders, obsessive compulsive disorder, restless leg syndrome and Tourette syndrome.